Show summary Hide summary
Former Nebraska senator Ben Sasse told CBS’s 60 Minutes this week that an experimental medication has significantly eased his symptoms and extended his life expectancy after his December revelation that he has stage 4 pancreatic cancer. The report puts a spotlight on a targeted therapy currently under federal review that researchers say could reshape treatment options for a disease with historically bleak outcomes.
In the interview broadcast April 26, Sasse described dramatic improvements since joining a clinical trial. Physicians initially gave him only months to live, he said, but he now reports far less pain and a substantial shrinkage of tumors following treatment with the investigational drug daraxonrasib.
Sasse said the combination of the trial drug and pain medication has made daily life more manageable. He credited “providence, prayer, and a miracle drug” for the turnaround and told the program he has seen roughly a three-quarter reduction in tumor volume over several months.
New York Times hit with lawsuit from US rights agency: claims white staffer was denied promotion
Horoscopes April 27: what every zodiac sign should expect today
What the drug does and why experts are watching
The medication under study was developed by Revolution Medicines and is given orally. It is designed to interfere with malignant signaling driven by mutations in the RAS family of genes — most notably the gene known as KRAS, which is mutated in the large majority of pancreatic cancers.
Dr. Christopher Lieu, an oncologist at the University of Colorado Anschutz, explained in February that the drug binds to the mutant protein and blocks its ability to drive tumor growth. Early investigators say that targeted action could deliver effective tumor control with fewer of the harsh side effects typically associated with systemic chemotherapy.
- Developer: Revolution Medicines
- Administration: daily oral dosing
- Target: mutations in the RAS/KRAS pathway
- Reported trial outcome: median survival of 13.2 months in the study cohort vs. about 6.7 months with standard chemotherapy
- Regulatory status: under review by the FDA; timeline may be expedited under a pilot program
Those survival figures, released by the company in mid-April, come from the trial population and will need confirmation in larger, randomized studies. The Food and Drug Administration is reviewing the therapy’s safety and efficacy; while standard reviews often take close to a year, a federal pilot program can accelerate consideration to a matter of weeks for some applications.
Patient experience, perspective and caveats
Sasse acknowledged his cancer has spread beyond the pancreas to his liver and lungs but said the treatment has reduced pressure on his spine and greatly lowered his pain levels. He also described relying on morphine as part of his symptom control.
Beyond immediate health effects, the diagnosis has prompted personal reflection. He told the program he has re-evaluated work and travel priorities, and that the illness has altered how he chooses to spend time with his family.
Medical experts stress caution: the drug has shown promise, but broader safety data and peer-reviewed results are needed before prescribing it as a new standard of care. Pancreatic cancer remains difficult to treat, and new therapies must demonstrate consistent, reproducible benefit across diverse patient groups.
For readers, the development matters because a safer, more targeted option could change prognosis for thousands of people. Even so, regulatory clearance is not the same as definitive proof of long-term benefit — and access, cost and eligibility for trials will shape how quickly patients can receive the medicine if it is approved.
In the short term, Sasse’s public account has drawn renewed attention to both the human stakes of pancreatic cancer and the promise of precision medicines that aim to neutralize specific genetic drivers of malignancy. The FDA review and upcoming trial data will determine whether daraxonrasib can move from hopeful anecdote to approved treatment.
